Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/3076% below fair value
$0.42+0.03 (+8.06%)
Close on Nov 13, 2026Market cap $8.14MP/E –Yield –
Ensysce Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ensysce Biosciences's enterprise value was $4.84M on Nov 11, 2026, against $3.63M a year earlier. Over the last 5 years it ranged from -$2.94M to $27.36B, with a median of $1.62M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.84M | +423.2% |
| 2025 | Dec 31, 2025 | $924.72K | -69.6% |
| 2024 | Dec 31, 2024 | $3.04M | +144.8% |
| 2023 | Dec 29, 2023 | $1.24M | -92.4% |
| 2022 | Dec 30, 2022 | $16.42M | -99.9% |
| 2021 | Dec 31, 2021 | $27.36B | -34.9% |
| 2020 | Dec 31, 2020 | $42.02B | +21.6% |
| 2019 | Dec 31, 2019 | $34.54B | +8.1% |
| 2018 | Dec 31, 2018 | $31.95B | – |
See a number that looks wrong?